Pharmacoeconomic review report Preservative-free latanoprost 50 [mu]g/mL ophthalmic solution (Monoprost) (Laboratoires Théa)
Preservative-free latanoprost (Monoprost) is available as a sterile ophthalmic solution in a single-dose container (50 mcg/mL). Health Canada approved Monoprost for the reduction of intraocular pressure (IOP) in patients with ocular hypertension (OH) or open-angle glaucoma (OAG). The manufacturer is...
| Autor principal: | |
|---|---|
| Autor Corporativo: | |
| Formato: | Libro electrónico |
| Idioma: | Inglés |
| Publicado: |
Ottawa (ON) :
CADTH
2018.
|
| Colección: | Common drug review clinical review report.
|
| Materias: | |
| Ver en Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820268506719 |
| Sumario: | Preservative-free latanoprost (Monoprost) is available as a sterile ophthalmic solution in a single-dose container (50 mcg/mL). Health Canada approved Monoprost for the reduction of intraocular pressure (IOP) in patients with ocular hypertension (OH) or open-angle glaucoma (OAG). The manufacturer is requesting that Monoprost be reimbursed as per the Health Canada-approved indication. The recommended dose is one drop in the affected eye(s) once daily. The manufacturer-submitted price was 20.54 per pack of 30 single-use containers, corresponding to a price of 0.68 per day. |
|---|---|
| Descripción Física: | 1 online resource (37 pages) : illustrations |
| Bibliografía: | Includes bibliographical references. |
